Showing 5731-5740 of 7115 results for "".
- Solta Medical Files for IPOhttps://practicaldermatology.com/news/solta-medical-files-for-ipo/2461072/Bausch Subsidiary Solta Medical Corporation is getting ready to go public. The Company publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering ("IPO") of Solta's common shares.
- Leadership Changes Take Place at SkinCeuticalshttps://practicaldermatology.com/news/leadership-changes-at-skinceuticals/2461069/Stephanie Kramer is now SkinCeutical’s Global General Manager, and Amy Sloan is the Head of SkinCeuticals U.S, the company reports Sloan brings 15 years of global and U.S. beauty industry experience - 10 of those years with SkinCeuticals - to the role of Head o
- Biofrontera Updates Patient Recruitment for Ameluz-PDT Trialhttps://practicaldermatology.com/news/biofrontera-updates-patient-recruitment-for-ameluz-pdt-trial/2461066/Fully 70 percent of the planned 186 patients have been enrolled in Biofrontera Inc.'s phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (Ameluz-PDT) in combination with the BF-RhodoLED lamp in the U.S, the company repor
- National Foundation for Cancer Research Taps NYC Dermatologist for Board Seathttps://practicaldermatology.com/news/national-foundation-for-cancer-research-taps-dermatologist-for-board-seat/2461065/The National Foundation for Cancer Research (NFCR) has announced that New York dermatologist Dr. Karen Burke and two others will be joining the board. NFCR was founded in 1973 to support cancer research and public education relating to the prevention, early diagnosis, better treatments
- Dupixent Update: Medication Shows Promise in Five Inflammatory Diseaseshttps://practicaldermatology.com/news/dupixent-update-medication-shows-promise-in-five-inflammatory-diseases/2461063/Dupixent (dupilumab) performed well across five diseases with underlying type 2 inflammation. The five diseases include eosinophilic esophagitis, chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. Additionally, positive result
- FDA Accepts Label Update for Suneva’s Plasma IQhttps://practicaldermatology.com/news/fda-accepts-label-update-for-sunevas-plasma-iq/2461061/Plasma IQ label, including the removal of the product's eye contraindication. The removal of this specific contraindication was due in part to a compilation of literature provided to the FDA showing the safety and efficacy of the ablative device on skin tissue, particular
- Desert Harvest's Aloe Glide Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/desert-harvests-aloe-glide-receives-nea-seal-of-acceptance/2461056/Desert Harvest’s Aloe Glide has received the National Eczema Association (NEA) Seal of Acceptance, making it the first sexual lubricant to earn this seal. The NEA Seal appears on products approved by the association to help consumers identify and choose products that are suitable
- Researchers Define Keys to Recognizing Ocular Rosaceahttps://practicaldermatology.com/news/researchers-define-keys-to-recognizing-ocular-rosacea-1/2461052/A number of eye symptoms may be more common in patients with rosacea compared to those without the skin disease, but the presence of conjunctival telangiectases may be the eye symptom most closely associated with rosacea. Findings come from a study in which researchers evaluated the rig
- Skyrizi Gets Psoriatic Arthritis Indicationhttps://practicaldermatology.com/news/skyrizi-gets-psoriatic-arthritis-indication/2461049/Skyrizi® (risankizumab-rzaa) from AbbVie is now approved for the treatment of adults with active psoriatic arthritis (PsA). FDA approval is supported by data from two pivotal studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated the efficacy a
- L'Oréal and Verily Partner to Advance Precision Skin Healthhttps://practicaldermatology.com/news/loreal-and-verily-partner-to-advance-precision-skin-health/2461048/L'Oréal and Verily, an Alphabet precision health company are joining forces to advance skin health. The partnership is expected to entail two programs aimed to better understand and characterize skin and hair aging mechanisms and to inform L'Oréal's precis